Google’s Isomorphic Labs, born from DeepMind’s AlphaFold breakthrough, is set to begin human trials of AI-designed drugs, aiming to speed up and cut costs in drug development. Backed by $600 million and partnerships with Novartis and Eli Lilly, this move could usher in a new era of faster, more precise, and personalized medicine.